Subscribe We areconvinced Billy Elliot that developing a treatment for RSV
By Admin
We areconvinced discloses adam cooper billy elliot that developing billy elliott details a treatment for RSV infection is an importanttherapeutic and commercial opportunity, and, like Alnylam, are committed toaddressing this need." "We are excited to have formed this new alliance with Cubist - a like-mindedorganization that shares our commitment to bringing a novel RNAi therapeutic topatients infected with RSV. We have tremendous respect for the Cubist team, andhave been impressed with the development and ongoing commercial success theyhave had with their lead anti-infective program, CUBICIN (daptomycin forinjection)," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam."Partnering this program brings additional critical mass to the advancement ofALN-RSV01 and/or second-generation RSV-specific RNAi therapeutics in our broaderprogram which we aim to advance through ongoing pre-clinical studies towardpotential clinical studies as early as 2010. The partnership also providesAlnylam with yet additional financial flexibility to invest beyond RSV in themultiple product opportunities represented by our growing pipeline of novel RNAitherapeutics Billy Elliot tickets ." In 2008, Alnylam conducted the GEMINI study in which ALN-RSV01 was evaluated ina double-blind, randomized, placebo-controlled Phase II clinical trial. Datafrom this study showed that intranasally administered ALN-RSV01 demonstratedstatistically significant anti-viral efficacy with an approximately 40% relativereduction in RSV infection rate and a 95% increase in the number ofinfection-free subjects, as compared with placebo. The RNAi therapeutic iscurrently being studied in a double-blind, randomized, placebo-controlled PhaseII clinical trial to assess the safety and tolerability of aerosolized ALN-RSV01in adult lung transplant patients naturally infected with RSV.
As a secondaryobjective, this trial will evaluate the anti-viral activity of ALN-RSV01 inpatients with a naturally acquired RSV lower respiratory tract infection best billy elliot . Basedon these and other data, Cubist and Alnylam will aim to maximize the value ofthe entire RSV program for advancement in pediatric and adult RSV-infectedpatients billy eliot musical . About Respiratory Syncytial Virus (RSV)RSV is a highly contagious virus that causes infections in both the upper andlower respiratory tract billy eliot tickets . RSV infects nearly every child at least once by the ageof two years and is a major cause of hospitalization due to respiratoryinfection in children and people with compromised immune systems, and others.RSV infection typically results in cold-like symptoms but can lead to moreserious respiratory illnesses such as croup, pneumonia, bronchiolitis, and inextreme cases, death billy eliot the musical . RSV infection in the pediatric and adult populationsaccount for more than 300,000 hospitalizations per year in the U.S. In addition,RSV infection in infants has been linked to the development of childhood asthma.As a result, there is a significant need for novel therapeutics to treatpatients who become infected with RSV.
About RNA Interference (RNAi)RNAi (RNA interference) is a revolution in biology, representing a breakthroughin understanding how genes are turned on and off in cells, and a completely newapproach to drug discovery and development biily elliot . Its discovery has been heralded as"a major scientific breakthrough that happens once every decade or so," andrepresents one of the most promising and rapidly advancing frontiers in biologyand drug discovery today which was awarded the 2006 Nobel Prize for Physiologyor Medicine tickets for billy elliott Billy Elliot tickets - imdb . RNAi is a natural process of gene silencing that occurs inorganisms ranging from plants to mammals billy elliott palace Billy Elliot tickets . By harnessing the natural biologicalprocess of RNAi occurring in our cells, the creation of a major new class ofmedicines, known as RNAi therapeutics, is on the horizon billie elliott .
RNAi therapeuticstarget the cause of diseases by potently silencing specific messenger RNAs(mRNAs), thereby preventing disease-causing proteins from being made billi elliot . RNAitherapeutics have the potential to treat disease and help patients in afundamentally new way About Cubist PharmaceuticalsCubist Pharmaceuticals, Inc billy elliott the musical . is a biopharmaceutical company focused on theresearch, development, and commercialization of pharmaceutical products thataddress unmet medical needs in the acute care environment billy eliot theatre . In the U.S Billy Elliot tickets - billyelliotbroadway ., Cubistmarkets CUBICIN® (daptomycin for injection), the first antibiotic in a new classof anti-infectives called lipopeptides Cubist has an agreement with AstraZenecato handle U.S cheap billy elliott tickets .
hospital sales for their established broad spectrum antibiotic,MERREM® I.V (meropenem for injection) . In addition to the collaboration withAlnylam on RSV announced today, the Cubist product pipeline includesecallantide, a recombinant human protein in Phase 2 clinical trials for theprevention of blood loss during cardiothoracic surgery; and two programs withrecently submitted INDs that address unmet medical needs to treat Gram-negativeinfections and CDAD (Clostridium difficile-associated diarrhea) Cubist isheadquartered in Lexington, MA billy elliott theatre . Additional information can be found at Cubist`sweb site at Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company developing novel therapeutics based onRNA interference, or RNAi billy eliott Billy Elliot tickets . The company is applying its therapeutic expertise inRNAi to address significant medical needs, many of which cannot effectively beaddressed with small molecules or antibodies, the current major classes ofdrugs . Alnylam is leading the translation of RNAi as a new class of innovativemedicines with peer-reviewed research efforts published in the world`s topscientific journals including Nature, Nature Medicine, and Cell. The company isleveraging these capabilities to build a broad pipeline of RNAi therapeutics;its most advanced program is in Phase II human clinical trials for the treatmentof respiratory syncytial virus (RSV) infection and is partnered with Cubist andKyowa Hakko. In addition, the company is developing RNAi therapeutics for thetreatment of a wide range of disease areas, including liver cancers,hypercholesterolemia, Huntington`s disease, and TTR amyloidosis.
Rambus' technology and productssolve customers' most complex chip and system-level interface challengesenabling unprecedented performance in computing, communications and consumerelectronics applications. National Hurricane Center Director Bill Read told Reuters in an interview. Price, who should have a long and fruitful All-Star career as a starter, is looking to channel 2002 Francisco Rodriguez and 2007 Joba Chamberlain to give the Rays one last kick to the finish line.Oh, and Evan Longoria will be back at the hot corner, too Billy Elliot tickets - billyelliotbroadway .Is it too much to ask the Sox to win two of three or sweep the trio of games at a stadium where we have yet to win this year? Well, keep in mind that many felt it was out of the Rays? grasp to do just that last week, but they exorcised their personal Fenway demons by taking advantage of a fastball-happy Jonathan Papelbon and a curious penchant for our sluggers to leave men on base.The pitching matchup in this series doesn?t tilt appreciably to one team, but it does give the Sox a very good chance at winning each game. Jaric’s $21 million deal is one of the ugliest in pro sports He will steal...